SynAct Pharma (Interview): Paving the Way for Clinical Validation
Idag, 10:10
Idag, 10:10
Following a high-energy Capital Markets Day, SynAct Pharma’s CSO and founder, Thomas Jonassen, joins us to discuss the roadmap for a transformational 2026. With upcoming Phase 2b data for the ADVANCE (RA) study in Q2, followed by a period of intense value creation through two other major clinical readouts. It is a truly exciting time for the company.
Idag, 10:10
Following a high-energy Capital Markets Day, SynAct Pharma’s CSO and founder, Thomas Jonassen, joins us to discuss the roadmap for a transformational 2026. With upcoming Phase 2b data for the ADVANCE (RA) study in Q2, followed by a period of intense value creation through two other major clinical readouts. It is a truly exciting time for the company.
Nvidia
Nvidia
1 DAG %
Senast

OMX Stockholm 30
0,61%
(15:54)
Hemnet Group
Idag, 15:04
Hemnet: Allt har sitt pris
Lucara Diamond
Idag, 13:28
Viaplay och Swedbank stiger
OMX Stockholm 30
1 DAG %
Senast
3 046,09